Elevai Labs, Inc. Common Stock

$2.11

(as of Jun 17, 11:14 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Elevai Labs, Inc. Common Stock

Stock Price

$2.11

Ticker Symbol

ELAB

Exchange

NASDAQ

Industry Information for Elevai Labs, Inc. Common Stock

Sector

Healthcare

Industry

Biotechnology

Company Description for Elevai Labs, Inc. Common Stock

Website

https://pmgcholdings.com

Country

USA

Full Time Employees

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Fundamentals for Elevai Labs, Inc. Common Stock

Market Capitalization

$2,860,811

EBITDA

$-3,880,816

Dividends per Share

P/E Ratio

Forward P/E Ratio

Earnings per Share

$-9.44

Earnings per Share Estimate Next Year

Profit Margin

Shares Outstanding

1,375,380

Percent Owned by Insiders

0.49%

Percent Owned by Institutions

2.99%

52-Week High

52-Week Low

Technical Indicators for Elevai Labs, Inc. Common Stock

50-Day Moving Average

200-Day Moving Average

RSI

39.82

ATR

0.28

Analyst Ratings for Elevai Labs, Inc. Common Stock

Strong Buy

Buy

Hold

Sell

Strong Sell

News About Elevai Labs, Inc. Common Stock

Jun 17, 2025, 9:04 AM EST

Northstrive Biosciences and Yuva Biosciences previously announced a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Phase II of this collaboration involves compiling a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases. See more.

Jun 16, 2025, 8:00 AM EST

Acquisition Target Specializes in Precision Milling, Turning, Mold Manufacturing, and Specialty Metals Expertise Serving Aerospace, Defense, and Industrial MarketsThis is PMGC’s third pending acquisition since April of 2025, demonstrating that its M&A strategy is well underway, with additional deals expected this year.PMGC Sees Significant Opportunity in Acquiring Additional US based CNC and Precision Manufacturing Companies Serving Aerospace, Industrial, and Defense Markets. See more.

Jun 14, 2025, 3:15 PM EST

[Top view of business office workstation with M&A letters or merger and acquisition] See more.

Jun 9, 2025, 8:43 AM EST

* PMGC Holdings (NASDAQ:ELAB [https://seekingalpha.com/symbol/ELAB]) announced on Monday the signing of a non-binding letter of intent to acquire a U.S.-based, cash-flow positive electronics contract manufacturing company with over 40 years of operational history. See more.